## REVION HEALTH CARE (UK) LIMITED

## Armour Pharmaceutical Company Limited B0000012/1 Pharmaceuticals Ltd.

## INTER OFFICE MEMORANDUM

CONFIDENTIAL

TO

DR. P. A. HARRIS

DATE: May 16, 1985

FROM

MR. R. B. CHRISTIE

REF: RBC/EB/7091

SUBJECT :

ARMOUR FACTORATE AND SEROCONVERSION TO HTLV-III POSITIVE

## COPIES TO :

Mr. C.J. Collins

As I have mentioned to you, there are strong indications that before heat treatment, a significant number of batches of our Factorate may have contained sufficient challenge of HTLV-III virus to induce at least seroconversion when administered to haemophiliac patients. No case of clinical AIDS has fortunately yet been reported to us in the U.K., although two children and four other patients are exhibiting "pre-AIDS syndrome" (lymphadenopathy,  $T_{4}$  lymphocyte depletion, thrombocytopenia, etc.)

Mr. Bishop received the attached letter from Dr. Parapia recently and this perhaps highlights the need for us to agree a consistent reply to such reports.

The situation known to me at the present is:

(1) Birmingham Children's Hospital (Dr. F. Hill)

32 patients (52% of those tested) HTLV3 Ab positive.

Batches believed to be involved = U16104, W78605, W98611, X39606, U61812.

Written report available.

(2) Hammersmith Hospital (Dr. J. Hows)

20 out of 30 patients tested were sero-positive (66.67%)

Batches believed to be involved = X76704, X24302, X43807 (with NHS), and X21902 which 2 patients have had exclusively!

Paper to be published but does not quote "Factorate" only "Commercial Concentrates".

(3) Bradford Royal Infirmary (Dr. L. Parapia)

1 patient only reported. Batch X47207.

Cont'd. ..

May 16, 1985

It should be stressed perhaps that at Birmingham and Hammersmith, direct links with the administration of Factorate is not clear cut in every case as some patients have had either NHS or other manufacturer's product or both.

GRO-C

R. B. CHRISTIE